Nanopharmaceuticals Market to 2027 - Global Analysis and Forecasts By Carrier Type ( Nanocrystals, Protein, Liposomes, Polymer, Inorganic and Other Carriers ); Application ( Anti-infective, Anti-inflammatory, Cardiovascular, Oncology, Neurology and Other Applications ); End User ( Hospital Pharmacies, Retail Pharmacies and Other Pharmacies )
Report Code: TIPRE00003418 No. of Pages: 150 Category: Pharmaceuticals Status: Upcoming
MARKET INTRODUCTION
Nanopharmaceuticals is an upcoming part of nanomedicine, which includes discovery/development and delivery of drugs using nanobiotechnology. It also includes the use of nanoparticles as therapeutic agents in various medical fields such as oncology, neurology, infectious diseases and others. nanopharmaceuticals are known to have different chemical, physical and biological properties as compared to its lager counterparts. These compounds have a larger surface area coupled with nano scale properties, which can be utilized to offer advancement in drug and gene development. The nanopharmaceuticals have wide scope that comprises smart material for tissue engineering aspects, intelligent tools for drug delivery aspects, diagnostics and others.
MARKET DYNAMICS
The nanopharmaceuticals market is anticipated to grow in the forecast period owing to driving factors such as rising prevalence of cardiovascular diseases, cancer and infectious diseases. In addition, the benefits of nanaopharmaceuticals over the macroscopic medicines is expected to offer significant growth opportunities in the market during the forecast period.
MARKET SCOPE
The "Global Nanopharmaceuticals Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of nanopharmaceuticals market with detailed market segmentation by carrier type, application, end user and geography. The global nanopharmaceuticals market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading nanopharmaceuticals market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global nanopharmaceuticals market is segmented on the basis of carrier type, application and end user. Based on carrier type, the market is segmented as nanocrystals, protein, liposomes, polymer, inorganic and other carriers. The nanopharmaceuticals market, based on application is segmented into, anti-infective, anti-inflammatory, cardiovascular, oncology, neurology and other applications. On the basis of end user, the global nanopharmaceuticals market is segmented into, hospital pharmacies, retail pharmacies and other pharmacies.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global nanopharmaceuticals market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The nanopharmaceuticals market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting nanopharmaceuticals market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the nanopharmaceuticals market in these regions.
MARKET PLAYERS
The reports cover key developments in the nanopharmaceuticals market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from nanopharmaceuticals market are anticipated to lucrative growth opportunities in the future with the rising demand for nanopharmaceuticals market in the global market. Below mentioned is the list of few companies engaged in the nanopharmaceuticals market.
The report also includes the profiles of key nanopharmaceuticals market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
• Abbott
• GlaxoSmithKline plc.
• Stryker
• Kadmon Holdings, Inc.
• Pfizer Inc.
• Kaken Pharmaceutical Co.,Ltd.
• Eli Lilly and Company
• Astellas Pharma Inc.
• Navidea Biopharmaceuticals, Inc.
• Novartis Pharmaceuticals Corporation
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
Nanopharmaceuticals is an upcoming part of nanomedicine, which includes discovery/development and delivery of drugs using nanobiotechnology. It also includes the use of nanoparticles as therapeutic agents in various medical fields such as oncology, neurology, infectious diseases and others. nanopharmaceuticals are known to have different chemical, physical and biological properties as compared to its lager counterparts. These compounds have a larger surface area coupled with nano scale properties, which can be utilized to offer advancement in drug and gene development. The nanopharmaceuticals have wide scope that comprises smart material for tissue engineering aspects, intelligent tools for drug delivery aspects, diagnostics and others.
MARKET DYNAMICS
The nanopharmaceuticals market is anticipated to grow in the forecast period owing to driving factors such as rising prevalence of cardiovascular diseases, cancer and infectious diseases. In addition, the benefits of nanaopharmaceuticals over the macroscopic medicines is expected to offer significant growth opportunities in the market during the forecast period.
MARKET SCOPE
The "Global Nanopharmaceuticals Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of nanopharmaceuticals market with detailed market segmentation by carrier type, application, end user and geography. The global nanopharmaceuticals market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading nanopharmaceuticals market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global nanopharmaceuticals market is segmented on the basis of carrier type, application and end user. Based on carrier type, the market is segmented as nanocrystals, protein, liposomes, polymer, inorganic and other carriers. The nanopharmaceuticals market, based on application is segmented into, anti-infective, anti-inflammatory, cardiovascular, oncology, neurology and other applications. On the basis of end user, the global nanopharmaceuticals market is segmented into, hospital pharmacies, retail pharmacies and other pharmacies.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global nanopharmaceuticals market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The nanopharmaceuticals market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting nanopharmaceuticals market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the nanopharmaceuticals market in these regions.
The reports cover key developments in the nanopharmaceuticals market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from nanopharmaceuticals market are anticipated to lucrative growth opportunities in the future with the rising demand for nanopharmaceuticals market in the global market. Below mentioned is the list of few companies engaged in the nanopharmaceuticals market.
The report also includes the profiles of key nanopharmaceuticals market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
• Abbott
• GlaxoSmithKline plc.
• Stryker
• Kadmon Holdings, Inc.
• Pfizer Inc.
• Kaken Pharmaceutical Co.,Ltd.
• Eli Lilly and Company
• Astellas Pharma Inc.
• Navidea Biopharmaceuticals, Inc.
• Novartis Pharmaceuticals Corporation
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Nanopharmaceuticals Market - By Carrier Type
1.3.2 Nanopharmaceuticals Market - By Application
1.3.3 Nanopharmaceuticals Market - By End User
1.3.4 Nanopharmaceuticals Market - By Region
1.3.4.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. NANOPHARMACEUTICALS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.3.1 North America - Pest Analysis
4.3.2 Europe - Pest Analysis
4.3.3 Asia-Pacific - Pest Analysis
4.3.4 Middle East and Africa - Pest Analysis
4.3.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. NANOPHARMACEUTICALS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. NANOPHARMACEUTICALS MARKET - GLOBAL MARKET ANALYSIS
6.1. NANOPHARMACEUTICALS MARKET - GLOBAL MARKET OVERVIEW
6.2. NANOPHARMACEUTICALS MARKET - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. NANOPHARMACEUTICALS MARKET - REVENUE AND FORECASTS TO 2027 - CARRIER TYPE
7.1. OVERVIEW
7.2. CARRIER TYPE MARKET FORECASTS AND ANALYSIS
7.3. NANOCRYSTALS
7.3.1. Overview
7.3.2. Nanocrystals Market Forecast and Analysis
7.4. PROTEIN
7.4.1. Overview
7.4.2. Protein Market Forecast and Analysis
7.5. LIPOSOMES
7.5.1. Overview
7.5.2. Liposomes Market Forecast and Analysis
7.6. POLYMER
7.6.1. Overview
7.6.2. Polymer Market Forecast and Analysis
7.7. INORGANIC
7.7.1. Overview
7.7.2. Inorganic Market Forecast and Analysis
7.8. OTHER CARRIERS
7.8.1. Overview
7.8.2. Other Carriers Market Forecast and Analysis
8. NANOPHARMACEUTICALS MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. ANTI-INFECTIVE
8.3.1. Overview
8.3.2. Anti-infective Market Forecast and Analysis
8.4. ANTI-INFLAMMATORY
8.4.1. Overview
8.4.2. Anti-inflammatory Market Forecast and Analysis
8.5. CARDIOVASCULAR
8.5.1. Overview
8.5.2. Cardiovascular Market Forecast and Analysis
8.6. ONCOLOGY
8.6.1. Overview
8.6.2. Oncology Market Forecast and Analysis
8.7. NEUROLOGY
8.7.1. Overview
8.7.2. Neurology Market Forecast and Analysis
8.8. OTHER APPLICATIONS
8.8.1. Overview
8.8.2. Other Applications Market Forecast and Analysis
9. NANOPHARMACEUTICALS MARKET - REVENUE AND FORECASTS TO 2027 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACIES
9.3.1. Overview
9.3.2. Hospital Pharmacies Market Forecast and Analysis
9.4. RETAIL PHARMACIES
9.4.1. Overview
9.4.2. Retail Pharmacies Market Forecast and Analysis
9.5. OTHER PHARMACIES
9.5.1. Overview
9.5.2. Other Pharmacies Market Forecast and Analysis
10. NANOPHARMACEUTICALS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Nanopharmaceuticals Market Overview
10.1.2 North America Nanopharmaceuticals Market Forecasts and Analysis
10.1.3 North America Market Forecasts and Analysis - By Carrier Type
10.1.4 North America Market Forecasts and Analysis - By Application
10.1.5 North America Market Forecasts and Analysis - By End User
10.1.6 North America Market Forecasts and Analysis - By Countries
10.1.6.1 United States Market
10.1.6.1.1 United States Market by Carrier Type
10.1.6.1.2 United States Market by Application
10.1.6.1.3 United States Market by End User
10.1.6.2 Canada Market
10.1.6.2.1 Canada Market by Carrier Type
10.1.6.2.2 Canada Market by Application
10.1.6.2.3 Canada Market by End User
10.1.6.3 Mexico Market
10.1.6.3.1 Mexico Market by Carrier Type
10.1.6.3.2 Mexico Market by Application
10.1.6.3.3 Mexico Market by End User
10.2. EUROPE
10.2.1 Europe Nanopharmaceuticals Market Overview
10.2.2 Europe Nanopharmaceuticals Market Forecasts and Analysis
10.2.3 Europe Market Forecasts and Analysis - By Carrier Type
10.2.4 Europe Market Forecasts and Analysis - By Application
10.2.5 Europe Market Forecasts and Analysis - By End User
10.2.6 Europe Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Market
10.2.6.1.1 Germany Market by Carrier Type
10.2.6.1.2 Germany Market by Application
10.2.6.1.3 Germany Market by End User
10.2.6.2 France Market
10.2.6.2.1 France Market by Carrier Type
10.2.6.2.2 France Market by Application
10.2.6.2.3 France Market by End User
10.2.6.3 Italy Market
10.2.6.3.1 Italy Market by Carrier Type
10.2.6.3.2 Italy Market by Application
10.2.6.3.3 Italy Market by End User
10.2.6.4 Spain Market
10.2.6.4.1 Spain Market by Carrier Type
10.2.6.4.2 Spain Market by Application
10.2.6.4.3 Spain Market by End User
10.2.6.5 United Kingdom Market
10.2.6.5.1 United Kingdom Market by Carrier Type
10.2.6.5.2 United Kingdom Market by Application
10.2.6.5.3 United Kingdom Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Nanopharmaceuticals Market Overview
10.3.2 Asia-Pacific Nanopharmaceuticals Market Forecasts and Analysis
10.3.3 Asia-Pacific Market Forecasts and Analysis - By Carrier Type
10.3.4 Asia-Pacific Market Forecasts and Analysis - By Application
10.3.5 Asia-Pacific Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Market
10.3.6.1.1 Australia Market by Carrier Type
10.3.6.1.2 Australia Market by Application
10.3.6.1.3 Australia Market by End User
10.3.6.2 China Market
10.3.6.2.1 China Market by Carrier Type
10.3.6.2.2 China Market by Application
10.3.6.2.3 China Market by End User
10.3.6.3 India Market
10.3.6.3.1 India Market by Carrier Type
10.3.6.3.2 India Market by Application
10.3.6.3.3 India Market by End User
10.3.6.4 Japan Market
10.3.6.4.1 Japan Market by Carrier Type
10.3.6.4.2 Japan Market by Application
10.3.6.4.3 Japan Market by End User
10.3.6.5 South Korea Market
10.3.6.5.1 South Korea Market by Carrier Type
10.3.6.5.2 South Korea Market by Application
10.3.6.5.3 South Korea Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Nanopharmaceuticals Market Overview
10.4.2 Middle East and Africa Nanopharmaceuticals Market Forecasts and Analysis
10.4.3 Middle East and Africa Market Forecasts and Analysis - By Carrier Type
10.4.4 Middle East and Africa Market Forecasts and Analysis - By Application
10.4.5 Middle East and Africa Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Market
10.4.6.1.1 South Africa Market by Carrier Type
10.4.6.1.2 South Africa Market by Application
10.4.6.1.3 South Africa Market by End User
10.4.6.2 Saudi Arabia Market
10.4.6.2.1 Saudi Arabia Market by Carrier Type
10.4.6.2.2 Saudi Arabia Market by Application
10.4.6.2.3 Saudi Arabia Market by End User
10.4.6.3 U.A.E Market
10.4.6.3.1 U.A.E Market by Carrier Type
10.4.6.3.2 U.A.E Market by Application
10.4.6.3.3 U.A.E Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Nanopharmaceuticals Market Overview
10.5.2 South and Central America Nanopharmaceuticals Market Forecasts and Analysis
10.5.3 South and Central America Market Forecasts and Analysis - By Carrier Type
10.5.4 South and Central America Market Forecasts and Analysis - By Application
10.5.5 South and Central America Market Forecasts and Analysis - By End User
10.5.6 South and Central America Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Market
10.5.6.1.1 Brazil Market by Carrier Type
10.5.6.1.2 Brazil Market by Application
10.5.6.1.3 Brazil Market by End User
10.5.6.2 Argentina Market
10.5.6.2.1 Argentina Market by Carrier Type
10.5.6.2.2 Argentina Market by Application
10.5.6.2.3 Argentina Market by End User
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. NANOPHARMACEUTICALS MARKET, KEY COMPANY PROFILES
12.1. ABBOTT
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. GLAXOSMITHKLINE PLC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. STRYKER
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. KADMON HOLDINGS, INC.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. PFIZER INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. KAKEN PHARMACEUTICAL CO.,LTD.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. ELI LILLY AND COMPANY
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. ASTELLAS PHARMA INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. NAVIDEA BIOPHARMACEUTICALS, INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. NOVARTIS PHARMACEUTICALS CORPORATION
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Nanopharmaceuticals Market - By Carrier Type
1.3.2 Nanopharmaceuticals Market - By Application
1.3.3 Nanopharmaceuticals Market - By End User
1.3.4 Nanopharmaceuticals Market - By Region
1.3.4.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. NANOPHARMACEUTICALS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.3.1 North America - Pest Analysis
4.3.2 Europe - Pest Analysis
4.3.3 Asia-Pacific - Pest Analysis
4.3.4 Middle East and Africa - Pest Analysis
4.3.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. NANOPHARMACEUTICALS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. NANOPHARMACEUTICALS MARKET - GLOBAL MARKET ANALYSIS
6.1. NANOPHARMACEUTICALS MARKET - GLOBAL MARKET OVERVIEW
6.2. NANOPHARMACEUTICALS MARKET - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. NANOPHARMACEUTICALS MARKET - REVENUE AND FORECASTS TO 2027 - CARRIER TYPE
7.1. OVERVIEW
7.2. CARRIER TYPE MARKET FORECASTS AND ANALYSIS
7.3. NANOCRYSTALS
7.3.1. Overview
7.3.2. Nanocrystals Market Forecast and Analysis
7.4. PROTEIN
7.4.1. Overview
7.4.2. Protein Market Forecast and Analysis
7.5. LIPOSOMES
7.5.1. Overview
7.5.2. Liposomes Market Forecast and Analysis
7.6. POLYMER
7.6.1. Overview
7.6.2. Polymer Market Forecast and Analysis
7.7. INORGANIC
7.7.1. Overview
7.7.2. Inorganic Market Forecast and Analysis
7.8. OTHER CARRIERS
7.8.1. Overview
7.8.2. Other Carriers Market Forecast and Analysis
8. NANOPHARMACEUTICALS MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. ANTI-INFECTIVE
8.3.1. Overview
8.3.2. Anti-infective Market Forecast and Analysis
8.4. ANTI-INFLAMMATORY
8.4.1. Overview
8.4.2. Anti-inflammatory Market Forecast and Analysis
8.5. CARDIOVASCULAR
8.5.1. Overview
8.5.2. Cardiovascular Market Forecast and Analysis
8.6. ONCOLOGY
8.6.1. Overview
8.6.2. Oncology Market Forecast and Analysis
8.7. NEUROLOGY
8.7.1. Overview
8.7.2. Neurology Market Forecast and Analysis
8.8. OTHER APPLICATIONS
8.8.1. Overview
8.8.2. Other Applications Market Forecast and Analysis
9. NANOPHARMACEUTICALS MARKET - REVENUE AND FORECASTS TO 2027 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACIES
9.3.1. Overview
9.3.2. Hospital Pharmacies Market Forecast and Analysis
9.4. RETAIL PHARMACIES
9.4.1. Overview
9.4.2. Retail Pharmacies Market Forecast and Analysis
9.5. OTHER PHARMACIES
9.5.1. Overview
9.5.2. Other Pharmacies Market Forecast and Analysis
10. NANOPHARMACEUTICALS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Nanopharmaceuticals Market Overview
10.1.2 North America Nanopharmaceuticals Market Forecasts and Analysis
10.1.3 North America Market Forecasts and Analysis - By Carrier Type
10.1.4 North America Market Forecasts and Analysis - By Application
10.1.5 North America Market Forecasts and Analysis - By End User
10.1.6 North America Market Forecasts and Analysis - By Countries
10.1.6.1 United States Market
10.1.6.1.1 United States Market by Carrier Type
10.1.6.1.2 United States Market by Application
10.1.6.1.3 United States Market by End User
10.1.6.2 Canada Market
10.1.6.2.1 Canada Market by Carrier Type
10.1.6.2.2 Canada Market by Application
10.1.6.2.3 Canada Market by End User
10.1.6.3 Mexico Market
10.1.6.3.1 Mexico Market by Carrier Type
10.1.6.3.2 Mexico Market by Application
10.1.6.3.3 Mexico Market by End User
10.2. EUROPE
10.2.1 Europe Nanopharmaceuticals Market Overview
10.2.2 Europe Nanopharmaceuticals Market Forecasts and Analysis
10.2.3 Europe Market Forecasts and Analysis - By Carrier Type
10.2.4 Europe Market Forecasts and Analysis - By Application
10.2.5 Europe Market Forecasts and Analysis - By End User
10.2.6 Europe Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Market
10.2.6.1.1 Germany Market by Carrier Type
10.2.6.1.2 Germany Market by Application
10.2.6.1.3 Germany Market by End User
10.2.6.2 France Market
10.2.6.2.1 France Market by Carrier Type
10.2.6.2.2 France Market by Application
10.2.6.2.3 France Market by End User
10.2.6.3 Italy Market
10.2.6.3.1 Italy Market by Carrier Type
10.2.6.3.2 Italy Market by Application
10.2.6.3.3 Italy Market by End User
10.2.6.4 Spain Market
10.2.6.4.1 Spain Market by Carrier Type
10.2.6.4.2 Spain Market by Application
10.2.6.4.3 Spain Market by End User
10.2.6.5 United Kingdom Market
10.2.6.5.1 United Kingdom Market by Carrier Type
10.2.6.5.2 United Kingdom Market by Application
10.2.6.5.3 United Kingdom Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Nanopharmaceuticals Market Overview
10.3.2 Asia-Pacific Nanopharmaceuticals Market Forecasts and Analysis
10.3.3 Asia-Pacific Market Forecasts and Analysis - By Carrier Type
10.3.4 Asia-Pacific Market Forecasts and Analysis - By Application
10.3.5 Asia-Pacific Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Market
10.3.6.1.1 Australia Market by Carrier Type
10.3.6.1.2 Australia Market by Application
10.3.6.1.3 Australia Market by End User
10.3.6.2 China Market
10.3.6.2.1 China Market by Carrier Type
10.3.6.2.2 China Market by Application
10.3.6.2.3 China Market by End User
10.3.6.3 India Market
10.3.6.3.1 India Market by Carrier Type
10.3.6.3.2 India Market by Application
10.3.6.3.3 India Market by End User
10.3.6.4 Japan Market
10.3.6.4.1 Japan Market by Carrier Type
10.3.6.4.2 Japan Market by Application
10.3.6.4.3 Japan Market by End User
10.3.6.5 South Korea Market
10.3.6.5.1 South Korea Market by Carrier Type
10.3.6.5.2 South Korea Market by Application
10.3.6.5.3 South Korea Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Nanopharmaceuticals Market Overview
10.4.2 Middle East and Africa Nanopharmaceuticals Market Forecasts and Analysis
10.4.3 Middle East and Africa Market Forecasts and Analysis - By Carrier Type
10.4.4 Middle East and Africa Market Forecasts and Analysis - By Application
10.4.5 Middle East and Africa Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Market
10.4.6.1.1 South Africa Market by Carrier Type
10.4.6.1.2 South Africa Market by Application
10.4.6.1.3 South Africa Market by End User
10.4.6.2 Saudi Arabia Market
10.4.6.2.1 Saudi Arabia Market by Carrier Type
10.4.6.2.2 Saudi Arabia Market by Application
10.4.6.2.3 Saudi Arabia Market by End User
10.4.6.3 U.A.E Market
10.4.6.3.1 U.A.E Market by Carrier Type
10.4.6.3.2 U.A.E Market by Application
10.4.6.3.3 U.A.E Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Nanopharmaceuticals Market Overview
10.5.2 South and Central America Nanopharmaceuticals Market Forecasts and Analysis
10.5.3 South and Central America Market Forecasts and Analysis - By Carrier Type
10.5.4 South and Central America Market Forecasts and Analysis - By Application
10.5.5 South and Central America Market Forecasts and Analysis - By End User
10.5.6 South and Central America Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Market
10.5.6.1.1 Brazil Market by Carrier Type
10.5.6.1.2 Brazil Market by Application
10.5.6.1.3 Brazil Market by End User
10.5.6.2 Argentina Market
10.5.6.2.1 Argentina Market by Carrier Type
10.5.6.2.2 Argentina Market by Application
10.5.6.2.3 Argentina Market by End User
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. NANOPHARMACEUTICALS MARKET, KEY COMPANY PROFILES
12.1. ABBOTT
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. GLAXOSMITHKLINE PLC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. STRYKER
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. KADMON HOLDINGS, INC.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. PFIZER INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. KAKEN PHARMACEUTICAL CO.,LTD.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. ELI LILLY AND COMPANY
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. ASTELLAS PHARMA INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. NAVIDEA BIOPHARMACEUTICALS, INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. NOVARTIS PHARMACEUTICALS CORPORATION
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies
1. Abbott
2. GlaxoSmithKline plc.
3. Stryker
4. Kadmon Holdings, Inc.
5. Pfizer Inc.
6. Kaken Pharmaceutical Co.,Ltd.
7. Eli Lilly and Company
8. Astellas Pharma Inc.
9. Navidea Biopharmaceuticals, Inc.
10. Novartis Pharmaceuticals Corporation
1. Abbott
2. GlaxoSmithKline plc.
3. Stryker
4. Kadmon Holdings, Inc.
5. Pfizer Inc.
6. Kaken Pharmaceutical Co.,Ltd.
7. Eli Lilly and Company
8. Astellas Pharma Inc.
9. Navidea Biopharmaceuticals, Inc.
10. Novartis Pharmaceuticals Corporation